ProMIS Neurosciences is trading 5.76% up at $14.14, with the move appearing mainly supported by biotechnology-sector strength; XBI is up 2.55% during regular trading.
- No new company-specific announcement was identified on September 18, 2026.
- Recent investor attention has centered on PMN310’s encouraging interim safety and biomarker data presented at September conferences.
- Latest conference coverage does not identify a September 18 catalyst or directly attribute the move to company news.